Clinical trial

A Phase I Trial of LY3143921 Hydrate in Solid Tumours

NCT03096054

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-06-21

PhasePHASE1

Study timeline

Study start (actual)2017-06-21Date precision: day

Registry last updated2026-08-18

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Colorectal Cancerunresolved

High Grade Serous Ovarian Cancerunresolved

Non Small-cell Lung Cancer (Squamous Cell Variant)unresolved

Urothelial Cancerunresolved

Breast Cancer (Triple Negative Type)unresolved

Pancreatic Cancerunresolved

Squamous Carcinoma of the Head and Neck (Human Papillomavirus (HPV) Negative)unresolved

Interventions

LY3143921 hydrateDRUG

Sponsors & collaborators

Cancer Research UKlead sponsor

Mapped research locations

GlasgowUnited Kingdom1 EdinburghUnited Kingdom1 Newcastle upon TyneUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03096054 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.